these factors include the broad heterogeneity of malignant neoplasms , the complexities of the drug-tumour interaction , difficulties in assessment of this interaction and the use of combinations of antineoplastic agents with cumulative efficacies and toxicities .
C0006826
malignant neoplasms
C0027651
tumour